The Filing Desk

Compass Therapeutics

CMPX · Nasdaq · Health Care · Financials, fiscal 2019 to 2025

CMPX · Last close · November 19, 2026
$0.68
Value Compass Therapeutics yourself

Compass Therapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$49 million. The diluted share count rose 14.8%.

COMPASS THERAPEUTICS, INC. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001171843-26-001337 Updated
Revenue
$0M
100.0%
Net margin
—
 
Net income
−$66M
 
Free cash flow
−$49M
 
Return on equity
−41.3%
5.2 pts
Market cap
$127M
Nov 19 close
P/E
—
 

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Operating margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Net margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs. Free cash flow margin for fiscal 2025 is blank: the 10-K's structured data doesn't include every figure it needs.

Charts show fiscal years, from the 10-K filings.

What Compass Therapeutics does

Compass Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-based cancer drugs. Clinical-stage means its drug candidates are still being tested in people and none is approved for sale. It focuses on how blood vessel growth, the immune system and tumor growth relate to each other.

It has four clinical product candidates. The lead one, tovecimig (CTX-009), is a bispecific antibody (one that binds two targets) aimed at DLL4 and VEGF-A. It is being tested with the chemotherapy drug paclitaxel in a Phase 2/3 trial in patients with biliary tract cancer who had one earlier treatment. The company says the trial met its main goal, with an overall response rate of 17.1% for tovecimig plus paclitaxel against 5.3% for paclitaxel alone. The other three are CTX-471, CTX-8371 and CTX-10726.

The company has no products approved for sale and has never earned revenue from product sales. It plans to test its candidates alone and in combination, and says it needs more financing to keep going.

Its biggest risks, as it describes them

  • It has no approved products, a history of significant losses, and may never be profitable.
  • It will need substantial additional financing, which may not be available on acceptable terms.
  • Clinical trials are lengthy and costly, and their results are uncertain.
  • Early or interim results may not predict later trial results.
  • Its antibody drugs are a new class of therapy, making time and cost hard to predict.
From Compass Therapeutics's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Compass Therapeutics lost money in fiscal 2025: a net loss of $66 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments144187152127209
Debt incl. finance leases00000
Net debt (negative means net cash)−144−187−152−127−209
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−221.3x————
Current ratio13.8x12.1x19.7x15.0x15.0x
Quick ratio13.8x12.1x19.7x15.0x15.0x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Compass Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Compass Therapeutics says to expect

  • Cash runwayBased on current operating plans, the anticipated cash runway is into 2028.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $8,750 of Compass Therapeutics shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 17, 2026Neil LernerChief Accounting OfficerBought10,000$0.59$5,900Form 4
Sep 24, 2026Neil LernerChief Accounting OfficerBought2,500$1.14$2,850Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score—2 of 82 of 8
Rule of 40———
Altman Z''16.113.286.28
Accruals ratio−1.1%−3.0%−9.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets rosePassFailFail
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailFailFail
Current ratio rosePassFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—PassFail
F-score—2 of 82 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Compass Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Compass TherapeuticsFY25−100.0%————2
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
AbCellera BiologicsFY25160.6%−289.0%−231.7%———Compare
Abeona TherapeuticsFY25—−1,536.9%−1,448.5%———Compare
AbsciFY25−38.2%−4,297.0%−3,358.3%−162.8%—3Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

8 years of figures

Fiscal yearFY19FY20FY20FY21FY22FY23FY24FY25
Income statement
Revenue—————010
Revenue growth———————−100.0%
Gross profit————————
Research and development—15152030384256
Operating income−0−28−28−82−42−50−57−73
Net income−0−30−30−82−39−42−49−66
Diluted EPS (US$)−0.01−0.96−0.96−1.31————
Diluted shares (millions)5313163105127137158
Cash flow
Cash from operations−0−27−27−20−34−41−45−49
Capital expenditure—0020000
Free cash flow—−27−27−21−34−41−45−49
Dividends paid00000000
Share buybacks00000000
Acquisitions00000000
Stock-based compensation—4445698
Balance sheet at fiscal year end
Cash and short-term investments04747144187152127209
Debt incl. finance leases—9900000
Total assets05252154200157140220
Total liabilities01212141881523
Shareholders' equity−04040140182148125197
Margins and ratios
Gross margin————————
Operating margin——————−6,661.8%—
Net margin——————−5,808.8%—
Free cash flow margin——————−5,282.2%—
Rule of 40 (growth + FCF margin)————————
Return on capital————————
Return on equity—−148.0%−148.0%−91.3%−24.4%−25.7%−36.1%−41.3%
Return on assets—−113.7%−113.7%−79.9%−22.2%−23.8%−33.2%−36.9%
Net debt to EBITDA————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Compass Therapeutics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Compass Therapeutics.